“In the coming months, we'll also start additional Phase III studies, as I mentioned, CDK4 in first line [indiscernible] breast cancer [indiscernible] in combination with pembrolizumab in PD-L1 high first-line non-small cell lung cancer and CAT 6 with positive breast cancer.”

In context

“a very importation for us in BRAF mutated colorectal cancer which is up to 10% of colorectal cancer, and that will be in the first line setting, a big unmet need because there's particularly poor prognosis patients presenting with BRAF mutated colorectal cancer. We also expect readouts for Veritex2 our ER [indiscernible] we codeveloping with ovens for ER-positive second-line plus methodic breast cancer and potentially for Crest which is a sasanlimab, a differentiated subcut PD-1 in combination with BCP in non-muscle invasive bladder cancer. We will also present in the coming months, Phase II randomized data for [indiscernible]. This is a randomized Phase II data in patients with prostate cancer. We've seen the data, and that provided us the confidence to initiate the 2 Phase III programs. In the coming months, we'll also start additional Phase III studies, as I mentioned, CDK4 in first line [indiscernible] breast cancer [indiscernible] in combination with pembrolizumab in PD-L1 high first-line non-small cell lung cancer and CAT 6 with positive breast cancer. Albert Bourla: So quite impressive on the Oncology side. Mikael, what about the rest? Mikael Dolsten: We thought we help you focus by this quarter displaying some nice movement, most valuable part of this chart, the right-hand. When you look over the next 18 months and including Oncology and non-Oncology, we will have up to 40 different opportunities to fill the left side that I hear you are eager to see progress on and the right hand. If you’ll include the 40 will be divided between potential approvals, projected pivotal readouts and potential proof of concept. And that did not even include early signals in clinical development. Operator: We'll take our next question from Steve Scala with TD Cowen. Steve Scala: Pfizer has previously stated, it anticipated having visibility on long-term C”